A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients with diagnosis of plaque-type psoriasis for at least 6 months

• Patients with plaque-type psoriasis covering at least 10% of the body

Exclusion Criteria:

• Patients with nonplaque forms of psoriasis

• Patients who have current drug-induced psoriasis

• Patients who are pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment

• Patients who had any previous treatment with infliximab or any therapeutic agent targeted at reducing tumor necrosis factor